Drug Profile
Lithium citrate - Medesis Pharma
Alternative Names: Lithium citrate tetrahydrate; NanoLithium®; NP-03Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Medesis Pharma
- Developer McGill University; Medesis Pharma
- Class Metals; Neuroprotectants
- Mechanism of Action Neuron modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Alzheimer's disease
- No development reported Huntington's disease
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease in Canada (Buccal)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Huntington's-disease(In volunteers) in France (Buccal)
- 20 Sep 2021 Phase-II clinical trials in Alzheimer's disease (In adults, In the elderly) in France (Buccal) (EudraCT-2021-001273-23) (NCT05423522)